Findings

What do systematic reviews say?

139 questions · 146 findings · 10 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 43 · 29.5%GRADE not reported 6 · 4.1%Very low 47 · 32.2%Low 29 · 19.9%Moderate 12 · 8.2%High 9 · 6.2%

Ascorbic acid vs placebo

Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Moderate

Ascorbic acid vs placebo

Serious adverse events · people with fatigue in peripheral neuropathy

Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
RR 0.7 [0.39, 1.27]
2 studies · 450 participants
Moderate

Amantadine vs placebo

Fatigue · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Change in activity limitations · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Participation · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
74 participants
Low

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Serious adverse events · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
80 participants
GRADE not reported

Ascorbic acid vs placebo

Reduction in fatigue · people with fatigue in peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ascorbic acid vs placebo

Fatigue · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 404 participants
Moderate

Ascorbic acid vs placebo

Change in activity limitations · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 406 participants
GRADE not reported

Neurodynamic mobilisation vs no treatment

Short‐term overall improvement (three months or less) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

It is very uncertain whether neurodynamic mobilisation changes short‐term overall improvement (three months or less) compared with no treatment (very low certainty).

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
RR 15 [1.02, 220.92]
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Adverse effects · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Short‐term improvement in CTS symptoms (pain) (3 months or less) ‐ At end of 12 weeks treatment (Protouch Keyboard) Scale: 0 to 10 · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Short‐term improvement in functional ability or health‐related quality of life (hand function) (three months or less) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

It is very uncertain whether neurodynamic mobilisation changes short‐term improvement in functional ability or health‐related… compared with no treatment (very low certainty).

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
RR 9 [0.59, 137.65]
1 study · 12 participants
Very low

Neurodynamic mobilisation vs no treatment

Improvement in neurophysiological parameters at ≤ 3 months · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Long‐term improvement in functional ability or health‐related quality of life (more than three months) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Neurodynamic mobilisation vs no treatment

Need for surgery · People with carpal tunnel syndrome on a waiting list for carpal tunnel release

It is very uncertain whether neurodynamic mobilisation changes need for surgery compared with no treatment (very low certainty).

1 finding from 1 review

Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
RR 0.33 [0.1, 1.12]
1 study · 14 participants
Very low

Night splinting vs no night splinting

Change in ankle dorsiflexion range of motion Lidcome Template in degrees. Scale from: 0.36 to 31.28. · patients with patients with reduced ankle range of motion in neuromuscular disease

1 finding from 1 review

Interventions for increasing ankle range of motion in patients with neuromuscular disease 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 52 participants
Very low